

DISCLOSURE

I have no financial, consulting, employment, or other business relationship with any vaccine manufacturers, vendors, organizations, or support groups.

Ŧ

Ŧ

OBJECTIVES

UPON COMPLETION OF THIS PRESENTATION, YOU WILL BE ABLE TO

- Describe the trialing & characteristics of common vaccines recommended during pregnancy and postpartum.
- Connect the timing, effectiveness, & safety of common vaccines in respect to the effect on the fetus.
- Create strategies for communicating with those who are vaccine hesitant of "anti-vaccine".

OUTLINE Introduction Vaccine Review Types of vaccines Trialing of vaccines Focus on the childbearing year Rationale for immunization Immune system in pregnancy Timing, effectiveness, & safety of common vaccines in respect to the effect on the feus or breastfeeding infant. Vaccine Hesitancy

- Definition & scope
- Strategies for communicating with those who are vaccine hesitant of "antivaccine".
 YOUR LIFE out putpose T

VACCINE REVIEW Since Jenner's discovery of smallpox vaccine in 1796, vaccination has grown from live-virus to multiple categories and types. New types continue to be researched globally to combat emerging illnesses. Public health safety requires adequate trialing and follow-up surveillance.

T







YPE	PROCESS	LIMITATIONS	EXAMPLES
nactivated	Use bacteria or virus that has been inactivated with heat, chemicals, or radiation	Not as strong immunity; May need several doses or boosters over time	Havrix/Hep. A Flu shot Polio shot Rabies
ive, ttenuated	Use bacteria or virus that has been attenuated (weakened) so as not to cause disease	May cause disease in immunosuppressed persons (e.g. pregnant)	MMR Varicella Smallpox Rota virus BCG Yellow fever

TYPES OF VACCINES: Whole Pathogen						
ТҮРЕ	PROCESS	LIMITATIONS	EXAMPLES			
Vector	Liquid or free-dried, large viruses (adenovirus, poxvirus) used as vectors; Gene(s) that encode the antigens of the pathogens are inserted into the large virus	Thrombotic thrombocytopenia;	J & J COVID only one in U.S. Ebola			
	EMERGING WHOLE	PATHOGEN VACCI	NES			
Chimeric	In human trials; Combine genetic "backbone" of parent virus and the protein outer capsule of the target virus	TBD	Zika			







TYPE	PROCESS	LIMITATIONS	EXAMPLES			
Include only the co best stimulate the i	mponents, or antigens that mmune system	All may require boosters for ongoing protection				
Polysaccharide	Sugars form the outer coating of many bacteria	Inadequate immune response in infants	H. influenza, type b (Hib)			
Conjugate	Sugar is conjugated (attached) to a protein antigen that improves recognizability by human body	Better immune response to bacteria	Hib Pneumococcal Meningococcal			
Foxoid	Aimed at disease-causing proteins (toxins) secreted by bacteria. The antigen (toxoid) is a chemically inactivated toxin.		Diptheria Tetanus			











ТҮРЕ	PROCESS	LIMITATIONS	EXAMPLES
DNA plasmid	A small piece of DNA (a plasmid) carries gene- encoding proteins from the pathogen of interest; enables rapid manufacturing in a short time Have been studied for over 30 years	Historically inefficient in getting to antigen-specific cells; Delivery route problematic Less potent Requires higher doses than mRNA vaccines Some theoretical uncertainty about effect on human genes.	NONE IN US Only one approved in India in 11/2021 for COVID; Numerous others in clinical trials; Other trials ongoing for use for HIV, Cancer, ZIKA, TB, Alzheimers, MS etc.













FOCUS ON CHILDBEARING YEAR: Rationale

- 1. Focus on those with greater morbidity and mortality in the maternal, fetal, and newborn populations.
- 2. Cost-effective way of reducing "under-five" mortality
- 3. Pregnancy is an immunologically dynamic state

High estrogen levels may modify the immune response May account for suboptimal responses to certain viral infections (flu, Hep.E, herpes simplex etc.)

T









COMMON U.S. VACCINES in REPRODUCTIVE YEARS

Covid-19	Meningococal (MenB)
Hepatitis A	Pneumococcal conjugate (PCV13)
Hepatitis B	Penumococcalpolysaccharide
Human Papillomavirus (HPV)	(PPSV23)
Influenza (inactivated)	Polio (IPV)
Influenza (LAIV)	Tetanus, Diphtheria, & Pertussis (Tdap) & Tetanus & Diphtheria (Td
Measles, Mumps, Rubella (MMR)	Varicella
Meningococcal (MenACWY or MPSV4)	Zoster
CDC. Guidelines for vaccinating pregnant women . Accessed	12/1/2022
	T

RECOMMENDATIONS	Vaccine*	Indicated During Every Pregnancy	May Be Given During Pregnancy in Certain Populations	Contraindicated During Pregnancy	Can Be Initiated Postpartum or When Breastfeeding or Both
and are available at	Inactivated influenza	$\chi^{1,1,2}$			XI
https://www.acog.org/clinical /clinical-guidance/committee-	Tetanus toxoid, reduced diphthoria toxoid and aceilular pertussis (Tdap)	X ^{1,14}			χi
philon/articles/2018/06/mat	Pneumococcal vaccines		χ^{656}		X ^{65,6}
Feb. 2020 Practice Advisory	Meningococcal conjugate (Men/ACWY) and Meningococcal serogroup B		XU		XU
Update recommends COVID-	Hepatitis A		X ^{ta}		XN
19 mRNA vaccination for all,	Hepatitis B		X ^(3,1)		X ^{rjji}
ncluding pregnancy, oostpartum, and breastfeeding	Human papillomavirus (HPV/**)(^{40,11,12}
	Measles-mumps-rubella			X ^{111,13,14}	X ^{III}
	Varicella			X ^{(1,10,16,16}	X ^{II}

VACCINATION RATES in PREGNANCY: 2020-2021 Influenza & Tdap (n = 1975) Tdap: 53.5% 70% provider initiated offer Disparities: higher rates among whites than AA and Hispanics Influenza: 54.5% 68% provider initiated offer Disparities: higher rates among whites & Hispanics than AA Reasons for not receiving (only 30.7% had both) Safety concerns

- Education (not knowing why needed)
- Not offered
 CDC (2021)

Ī

COVID-19 VACCINATIONS: All Groups





GENERAL GUIDELINES: Pregnancy

- COVID-19 & influenza if not done before
- Tdap in 3rd Trimester
- Halt HPV doses if not completed
- Other vaccine recommendations depend on individual factors and risk exposure (e.g. travel, occupational, previous conditions)
- No known fetal risk from passive immunization of pregnant women with immune globulin preparations.

GENERAL GUIDELINES: Breastfeeding

- Live-virus, inactivated, recombinant, subunit, polysaccharide, conjugate and toxoids pose no risk for mother or baby. (CDC)
- Rubella might be excreted in breastmilk, but does not infect infant. In rare case it might, is well-tolerated because virus is attenuated. (CDC)
- To date, mRNA COVID-19 is safe and IgG & IgM antibodies higher in breastmilk of women who have breastfed for 24 months. (Girardi & Brenner, 2022)

DIPTHERIA, TETANUS, PERTUSSIS

- DPT, DTwP, DTaP, Tdap ?????
- **DPT/DTwP**: live, inactivated Bordetella pertussis (aka "whole cell"), full dose of diptheria & tetanus toxoids
- **DTaP**: full dose of diptheria & tetanus toxoids; full dose of pertussis subunits (aka "acellular")
- **Tdap**: full dose of tetanus toxoid; reduced dose of diptheria toxoid and acellular pertussis

ہ تک

Ŧ

Tdap

Public Health Issue

Waning global immunity to pertussis

Purpose of Prenatal Administration

Maximize maternal antibody response

Maximizes passive antibody transfer to the infant

Tdap Effectiveness

Reduces risk of infant (0-3 mo.) pertussis by 78%.

Reduces infant hospitalizations for pertussis by 90%. Current research does not show a negative impact on

infants ability to mount their own response to TDaP later...continuing to be studied.

CDC (2017)

Tdap Timing

When: 27-36 wks. Gestation

Repeat every pregnancy

Consider single dose for those in close contact (e.g. other parent, siblings, grandparents)

Ŧ

Tdap FAQs

Why 27-36 wks? ... Why not give postpartum?

- 1. Maximizes maternal antibody response
- 2. Maximizes passive antibody transfer to infant.
- 3. Most vulnerable infant period is 0-3 months & takes 2 wks. To start developing antibodies.
- 4. Breastmilk has not been found to be protective against pertussis.

Tdap FAQs

Why give every pregnancy?

Pertussis immunity begins to wane quickly: within 2-4 months.

Why consider other family/close contacts?

Cocooning decreases chances of exposure. It is believed that most early infant exposures to pertussis are from family members with waning immunity.

(CDC)



INFLUENZA "Influenza is more likely to cause severe illness in pregnant people than in people of reproductive age who are not pregnant. Changes to the immune system, heart, and lungs during pregnancy make people more susceptible to influenza severe enough to cause hospitalization throughout pregnancy and up to two weeks postpartum. Influenza also may be harmful for the developing baby. A common influenza symptom fever may be associated with neural tube defects and other adverse outcomes for a developing baby. Parental vaccination also can help protect a baby from influenza after birth (because antibodies are passed to a developing baby during pregnancy)." CDC (2022). Flu and Pregnancy "Most severe during the last three months of pregnancy." Arora & Lakshmi (2021) T

Types of Flu Vaccines: LAIV

- Live attenuated influenza vaccine (LAIV) is contraindicated in pregnancy.
- Flumist® Quadrivalent
- Intranasal route

Types of Flu Vaccines: Inactivated-Historical (Arora & Lakshmi, 2021) (CDC, 2021)

- Inactivated influenza vaccine (IIV):IM or intradermal
- Inactivated monovalent non-adjuvanted pandemic influenza vaccine
- Inactivated monovalent adjuvanted H1N1 pandemic influenza vaccine (MF59, AS03, & aluminum phosphate adjuvanted). AS03adjuvanted H1N1 2009 vaccine produces a protective antibody response in 93% of pregnant women.

Ŧ

- Trivalent vaccine: type A (H1N1), type A (H3N2), & type B
- Recombinant influenza vaccine (RIV) (trivalent): IM only

Types of Flu Vaccines: Inactivated-CURRENT (CDC, 2021)

2021-2022: ALL FLU VACCINES ARE QUADRIVALENT

Added a second B type

Recombinant quadrivalent & cell-culture based are egg free

Ŧ

T

1. Flucelvax® quadrivalent

2. Flublok® quadrivalent

Adverse Effects of Flu Vaccine

- Local reactions most common (20%)
- Allergic reactions very rare
- Guillaine Barre syndrome low in general population, but have a greater likelihood of developing it IF have a history....Post-licensure safety monitoring has found no association between GB & LAIV

Arora & Lakshmi (2021)





COVID-19 DISEASE

Compared to non-pregnant persons, COVID-19 infection during pregnancy is associated with increased risk of following:

- Maternal severe illness
- Intensive care unit admission
- Mechanical ventilation
- Death
- Preterm birth, & possibly stillbirth
- Thromboembolic disease
- Hypertensive disorders
- Cesarean delivery
 (ACOG; CDC; Girardi & Bremer, 2022; Stafford et al, 2021)

COVID-19 DISEASE

- Higher risk for those with comorbidities (diabetes, obesity, advanced maternal age, and cardiovascular disease).
- Higher rate of infection and death in certain racial/ethnic groups.
- Rare (2-3%) vertical transmission with minimal persistent neonatal infection

(ACOG; Stafford et al, 2021)

COVID-19 VACCINE TYPES

- ACOG: mRNA (Pfizer & Moderna) preferred
- CDC: all acceptable (including Johnson & Johnson viral vector)

ī

COVID-19 VACCINE TIMING

- Give as soon as possible to increase antibodies
- Can give anytime
- Full series with booster, according to current schedule.

COVID VACCINE SAFETY CONCERNS THAT HAVE BEEN RAISED

Ŧ

T

- Menstruation and fertility
 - Increased cycle length
 - Decreased fertility: Spike protein similar to synctin-1 protein involved in implantation and placentation
 - mRNA accumulation in the ovaries
- Pregnancy
 - Infection
 - Complication due to acute or chronic placental insufficiency
 - Increased pregnancy loss

COVID VACCINE SAFETY CONCERNS THAT HAVE BEEN RAISED

- Poor Newborn Outcomes
 - Teratogenicity from maternal fever after vaccine
 - Preterm birth or stillbirth
- Safety of Breastfeeding

STATE OF THE COVID VACCINE SCIENCE (Girardi & Bremer, 2022)

Menstruation & fertility

•

- CYCLE LENGTH: Temporary, one day increase in menstrual cycle in a small number of the >72 million females who have received a vaccine.
- FERTILITY: Hypthetical cross-reactivity protein issue: only share 4 amino acids. Studies report no antibodies bind to synctim....If this did occur, though, would cause sterility by natural antibodies from the disease as well as the vaccine—which has not been reported.
- ACCUMULATION IN OVARIES: Low biodistribution found in ovaries & testes. No performance in animal studies on female mating performance, fertility or any ovarian/uterine parameters

STATE OF THE COVID VACCINE SCIENCE (Girardi & Bremer, 2022)

• Menstruation & fertility (continued)

- Human studies have found no effect on ovarian follicular function.
- In study of frozen embryo transfer, no effect on embryo implantation or early development. Post-infection and post-vaccine studied (Pfizer & Moderna)

CONCLUSION: NO SCIENTIFIC EVIDENCE THAT THE COVID-19 VACCINE HAS DELETERIOUS EFFECTS ON FEMALE FERTILITY.

STATE OF THE COVID VACCINE SCIENCE (Girardi & Bremer, 2022)

Infection

•

- Vaccine associated with lower odds of severe COVID-19 in pregnancy.
- Less like to get COVID-19
- Complications from acute/chronic placental insufficiency
- Histologic exam of placentae show no increased incidence of insufficiency
- Not associated with increased pregnancy or delivery complications

STATE OF THE COVID VACCINE SCIENCE (Girardi & Bremer, 2022)

Pregnancy loss

- No additional risk of spontaneous abortion with preconception or early pregnancy vaccination.
- pregnancy vaccination. Self-reported losses: can not know all data and rate is consistent with general population

Newborns

- TERATOGENICITY from maternal fever: studies reveal mild fever to date, not
- the high fever that would cause teratogenicity
- No concerns found to date; may actually be protective

Breastfeeding

•

Protective antibodies in breastmilk, increased with breastfeeding longevity.















VACCINE CRITICS: 3 groups

- 1. Activists who are against vaccines
- 2. Support groups for those considered to be victims of vaccines
- 3. Political parties trying to gain backing for their cause from social groups or a religion
- Those in groups 2 & 3 rarely produce new arguments, but they do diffuse their views wider and frame arguments in a wider worldview.

T

Those who actively criticize in public are often motivated by profit.

WHAT DETERMINES IF ONE IS VACCINE HESITANT

- Education & socio-economic status DO NOT influence
- CONTEXTUAL INFLUENCES
 Historic, socio-cultural, environmental, health system
- INDIVIDUAL/GROUP INFLUENCES
 Personal perception of vaccine; the social/peer environment
- VACCINE/VACCINATION-SPECIFIC
 SAGE Working Group on Vaccine Hesitancy. (2015).





Ŧ

Etzioni-Friedman (2021) & Etzioni & CDC (2020)

COMMUNICATION EXAMPLES: Past Decade

- 1. Allegations of correlation between autoimmune manifestations and vaccination.
 - Several rare anecdotal reports, but not found in largescale studies.
- 2. "Autoimmune/inflammatory syndrome induced by adjuvants" (aluminum)
- Study (n=18,000) found lower rate of autoimmune disorders among those who underwent allergic immunotherapy, which contains aluminum nl-Friedman (2021) & Etzioni & CDC (2020)

MEDIA COMMUNICATION

- 1. Media "balance" (presenting both sides) influences audience's perception of safety.
- Negatively impacts vaccine intentions
- Gives false impression that there is no scientific consensus of safety & efficacy
- Internet/social media users more likely to be hesitant

Search engines compound exposures based on previous search patterns: blurs boundaries of quality information

1

PROVIDER COMMUNICATION

• MDs & RNs most trusted source.

- BUT, tend to refrain from consults & the hesitant feel alienated because of this.
- ✓ 5-50 fold increase in vaccine acceptance if offered/encouraged by provider
- ✓ More likely to recommend if have awareness & knowledge of the vaccine.
- ✓ Confidence & willingness to recommend increased with societal & colleague support.
- Most agree on importance, but feel overworked and have inadequate training to discuss.
- CAM providers: ideal consultation visits





STRATEGIES (1)

Enhancing Vaccine Uptake

- Go beyond the knowledge deficit approach
- Use risk communication strategies that capitalize on heuristics
- Dispel associations of adverse effects with vaccines
- 3 step approach for critics:
 - Identify technique being used
 - Identify the topic
 - Respond by naming the technique and relating it to the topic being raised

LIFE our sur

T

STRATEGIES (2)

- If someone continues to refuse after an explanation, respect their decision, document in health record, and continue to offer again at each visit. Do not discharge from the practice.
- Mandatory policies are saved for situations when there is an increase in vaccine hesitancy and refusal. Does not address the underlying causes of hesitancy and refusal.

STRATEGIES (3)

Three Step Approach for Critics

- STEP I: Identify technique being used
 - Conspiracy theory
 - Reference to fake experts
 - Selectivity in evidence used to criticize (i.e. cherrypicking studies)

Ŧ

Ŧ

Ŧ

- Impossible expectations (i.e. 100% safety)
- Misrepresentations or false logic

STRATEGIES (4)

Three Step Approach for Critics

- STEP 2: Identify the topic
 - Distrust in health authorities & providers
 - Low threat of disease
 - Lack of vaccine effectiveness
 - Unsafe vaccine
 - Alternatives to vaccine

STRATEGIES (5)

Three Step Approach for Critics

- STEP 3: Respond using one of the following key messages in Step 1 with one in Step 2:
 - Unmask the technique being used
 - Relate it to the topic being raised
- THIS 3 STEP APPROACH HAS BEEN SHOWN TO MITIGATE THE INFLUENCE OF A SCIENCE DENIER AND DOES NOT BACKFIRE.

23

REFERENCES

ACOG Committee Opinion No. 741: Maternal Immunization. Obstet Gynecol. 2018 Jun;131(6):e214-e217. doi: 10.1097/AOG.000000000002662. PMID: 29794683. Arora, M., & Lakshmi, R. (2021). Vaccines - safety in pregnancy. Best practice & research. Clinical obstetrics & gynaecology, 76, 23-40. https://doi.org/10.1016/j.bpobgyn.2021.02.002 Brucker, M., & King, T. (2017). Pharmacology for women's health. Burlington, MA: Jones & Bartlett. Centers for Disease Control and Prevention (CDC). (N.D.) Science summary: CDC studies on thimersol in vace 1/2/2022 from https://www.cdc.gov/vaccinesafety/pdf/cdestudieson/vaccinesandautism.pdf Centers for Disease Control and Prevention (CDC). (2016). Guidelines for vaccinating pregnant women.: guidance of the Advisory Committee on Immunization Practices (ACIP). Accessed 1/2/2022 from <u>https://www.edc.gov/vaccines/genancy/hep-todisfirgindleins.html</u> Centers for Disease Control and Prevention (CDC).. (2020). Vaccine safety: thimersol and vaccines. Accessed 1/2/2022 from https://www.ede.gov/vaccinesafety/concerns/thimerosal/index.html Centers for Disease Control and Prevention (CDC). (2021). Flu and pregnancy. Accessed 2/20/22 from https://www.cdc.gov/flu/highrisk/pregnant.htm Centers for Disease Control and Prevention (CDC). (2021). Flue and Tdap vaccination coverage among pregnant women-United States, April 2021. Accessed 2/10/2022 from https://www.edc.gov/flu/fluvaxview/pregnant-women-gpr/2021.htm Centers for Disease Control and Prevention (CDC.). (2021). Influenza (flu). Accessed 2/20/22 from https://www.ede.gov/flu/season/faq-flu-season-2021-2022.html Ŧ

REFERENCES

- Centers for Disease Control and Prevention (CDC). COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2022, February 20. https://covid.cdc.gov/covid-data-tracker
- Centers for Disease Control and Prevention (CDC). (2022). Understanding mRNA COVID-19 vaccines. Accessed 2/10/2022 from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mRNA.html
- The state of th
- Vaccuer, Frank, 267/000, 2000. Safety of Reduced-Dose Intrademal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis. JAMA Netre Open. 2021;4(2):e2035693. doi:10.1001/jamanetworkopen.2020.35693 Egun
- Etzioni-Friedman T, Etzioni A. Adherence to Immunization: Rebuttal of Vaccine Hesitancy. Acta Haematol. 2021;144(4):413-417. doi: 10.1159/000511760. Epub 2020 Nov 17. PMID: 33202404; PMCID: PMC7705945.
- Grandi G, Bernner AA, Scientific Fordone Supporting Concurring Disease 2019 (2014). 2014 (2014) (

REFERENCES

- Hong Sun Approximation and evaluation of the spontaneous abortion rate following COVID-19 vaccination in pregnancy. American Journal of Obstetrics & Gynecology MFM. 2022; 4(1):100510. <u>https://doi.org/10.1016/aj.aj.ourg/121.100510</u>.
 Laxi N, Giovanazzi A, Capuano A, Cristafulli S, Cuttoneo PM, Fantini MF, Ferrajolo C, Moretti U, Poluzzi E, Raschi E, Ravaldi C, Reno C, Tictoro M, Vamaczi A, Zanoti G, Triffor G, Ilaniovacino COVID19 sollaborating group. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocomptomised Patients, and Persons with Fistory of Allergy or Prior SARS-CoV-2 Infection. Dorview of Current Recommendations and Pro-au Post Amirkating Evidence for Vaccune Efficacy and Sattry. Dung Str. 2021 Dec;44(12):1247-1269. doi: 10.1007/s0254621-01131-6. Epab 2021 Nov S. PMID: 34739716;
- Donald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and dete 2015 Aug 14;33(34):4161-4. doi: 10.1016/j.vaccine.2015.04.036. Epub 2015 Apr 17. PMID: 25896383. Mac
- 2015 Aug 1432(4)440104-. doi: 10.1016/j.secute.2015/04.006. Epite 2015 Aug 11.7 PMIR-2509055.
 Revendante AR, Law AV. Will Hoy, Yoan Work they? Examining pairent vaccine intention for flan and COVID-19 using the Health Belief Media. Res Social Adm Pharm. 2021 Sept 7(9):1596-1605. doi: 10.1016/j.septarm.2020.12.012. Epite 2020 Des 30, PMID: 35411259; PMCID: PMC/7832842.
- Orije MRP, Larivière Y, Herzog S, Mahieu LM, Van Damme P, Leuridan E, Maertens K. Breast Milk Antibody Levels in Tdip-Vaceinated Women After Freterm Delivery. Clin Infect Dis. 2021 Sep 15:73(6):e1305-e1313. doi: 10.1093/aid.eia260. PMID. 33788227.
- Our World in Data. Coronavirus pandemic (COVID-19). Acessed 2/20/2022 from <u>https://corwerldindeta.org/coronavirus</u> Pandolfi E, Gesualdo F, Carloni E, Villani A, Midalla F, Carsetti R, Stefanelli P, Fedele G, Tozzi AE; Pertussis Study Group. Does Breastfeding Protect Young Infants From Pertussis? Case-courdo Study and Immunologic Evaluation. Pediatr Infect Die J. 2017 Marzifo(5):e84-53. doi: 10.1097/INF.000000000141 R JMID: 2770012.

Ŧ

Ŧ

REFERENCES

- Paterson P. Meurice F. Stanbery LR, Glismann S. Rosenthal SL, Larson HJ. Vaccine hesitancy and healthcare providers. Vaccine. 2016 Dec 20:44(2):e700-6706. doi: 10.1016/j.sccine.2016.10.042. Epib 2016 Oc 31. PMD: 72710314. Stafford JA. Predem JG, Shai IM. The convension disease 2019 vaccine in pregmancy risks. heards, and recommendations. And J Obstet Gynecol. 2021 May:224(5):484-495. doi: 10.1016/j.ajog.2021.01.022. Epib 2021 Jan 30. PMID: 33529575; PMCD: Dr.PMC7847190.

 Tebas P. Roberts CC, Muthumani K. Reuschel EL, Kuchoharker SB, Zaidi FL, White S, Khan AS, Bacine T, Choi H. Boyer J. Park NX: Thrist S. Romijos CI, Kinger D, SymUB: Regarizzi M, Koharger GP, Wiener DM, Kashoy JN. Satity and Immunogenicity of an Anti-Zika Virus DNA Vaccine Preiminary Report. N Engl J Med. 2017 Oct 41.01056N:EMod.1708120. doi: 10.1056/NE.Hond.1708120. Epib ahead of print. PMID: 28976859; PMCID: PMCK824015. PMCH Mark Torganization (WHO). Ten threats to global health in 2019. Accessed 1/15/2022 from <u>https://www.who.int/new- teom/specific/time-threat-to-global-health-in-2019</u>

YOUR LIFE out purpose	Ċ

